定了!药明生物宣布在石家庄筹建中国北方最大生物药研发生产中心 行业动态
来源:药明生物 时间:2018-05-17 评论: 0 阅读: 1261 A+ A-
导读

​16日,药明生物(WuXi Biologics, 2269.HK)宣布,在河北石家庄高新区筹建世界领先的生物药一体化研发生产中心,旨在为全球生物药开发、临床生产及商业化生产提供一体化解决方案。

16日,药明生物(WuXi Biologics, 2269.HK)宣布,在河北石家庄高新区筹建世界领先的生物药一体化研发生产中心,旨在为全球生物药开发、临床生产及商业化生产提供一体化解决方案。预计项目一期工程将于2020年投产。


QQ图片20180517095210.png


项目签约仪式在北京隆重举行

 

药明生物石家庄生物药一体化研发生产中心将由工艺开发实验室、产能5,000升的临床样品生产基地(药明生物九厂)和产能48,000升的商业化生产基地(药明生物八厂)组成,其设计及建设将符合美国、欧盟及中国的cGMP标准。此举将使药明生物成为更深、更广、更宽的生物药研发生产赋能平台,助力提升石家庄生物制药产业的能力和地位,为我国药品上市许可持有人制度(MAH)政策提供产能支持,同时服务范围也将辐射全球。


QQ图片20180517095221.png


药明生物全球生产副总裁董健先生代表公司签约


“我非常高兴药明生物能筹建中国北方最大的生物药研发生产中心,这将有助于我们借力区域政府支持,吸引更多本地优秀人才,赋能当地合作伙伴更高效地研发生产生物药,同时为全球合作伙伴提供更强大的供应链网络。”药明生物首席执行官陈智胜博士表示,“考虑到药明生物平台上研发的161个项目未来可期的生产需求,我们将基于此次投资,快速高效地加强生产业务规模和能力,将药明生物打造成为全球生物药商业化生产服务领域的领导者。”


关于药明生物

药明生物作为一家香港上市公司,是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,帮助任何人、任何公司发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。如需更多信息,请访问:www.wuxibiologics.com.cn。


WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang


BEIJING, China, May 16, 2018


WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to build an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, capital of Hebei province in northern China.‬

 

The new state-of-the-art biologics center will include process development labs, clinical manufacturing facility (MFG9) with 5,000 L bioreactor capacity and commercial manufacturing facility (MFG8) with 48,000 L bioreactor capacity which will be built to meet cGMP standards of the United States, the European Union, and China. Besides serving global clients, the new integrated center will also support Marketing Authorization Holder (MAH) system in China and address urgent needs of Chinese partners. Initial phase of the center will be operational in 2020.


QQ图片20180517095241.png


“We are very pleased to establish the largest biologics center in northern China, which will enable local companies to more effectively develop and manufacture biologics and in the meantime provide a robust supply chain network for our global clients. This expansion will allow us great access to local talents, markets and government support.” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. “With this investment and current 161 biologics programs that WuXi Biologics will manufacture, we will quickly and cost effectively expand our manufacturing capacity to meet our partners’ needs and become one of the global CMO leaders.”


About WuXi Biologics


WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit


药智公众号二维码.jpg

广告
游客需要先 登录 才能评论
评论(0)
暂无评论
热门推荐
在双节来临之际,药智推出大数据系列宝典助您在医药前路上步步进...
3天前 阅读: 2385
日前,国家医保局主导的试点联合采购在上海召开座谈会,公布了第...
3天前 阅读: 846
上海市将自9月30日起对部分纳入该市医保支付的抗癌药协议采购...
6天前 阅读: 893
9月14日,在国家卫生健康委员会机关2号楼,在国家卫健委新闻...
1星期前 阅读: 936
近期,中成药价格暴涨的消息在全国各地“刷屏”,患者压力骤增,...
1星期前 阅读: 667
正当业界对2018年底一致性评价会否延期心存侥幸的时候,上海...
2星期前 阅读: 981
8月底,国务院常务会议宣布,完善国家基本药物制度,有利于满足...
2星期前 阅读: 1085
对抗“超级细菌”有了更有效的抗生素。5日,记者从重庆大学获悉...
2星期前 阅读: 992
江苏省指出对在全国同品种前3家通过仿制药质量和疗效一致性评价...
2星期前 阅读: 1283